US Broker Ratings

Exact Sciences Corporation (EXAS) Stock Analysis: Navigating Growth with a 23% Revenue Surge

Exact Sciences Corporation (NASDAQ: EXAS) is making waves in the healthcare sector with its focus on innovative cancer screening and diagnostics. This Wisconsin-based company has a robust portfolio that includes..

ADMA Biologics Inc (ADMA): Investor Outlook with Potential for 155% Upside

ADMA Biologics Inc (NASDAQ: ADMA), a biopharmaceutical company focused on plasma-derived therapeutics, has been gaining attention for its promising growth potential within the healthcare sector. With a current market capitalization..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 59% Potential Upside Amidst Strong Buy Ratings

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a pioneering entity in the biotechnology sector, is garnering significant attention from investors due to its promising growth potential in the treatment of rare neuroendocrine..

McKesson Corporation (MCK) Stock Analysis: Is the 12.82% Upside an Opportunity for Investors?

McKesson Corporation (NYSE: MCK) stands as a formidable entity within the healthcare sector, specifically in the medical distribution industry. With a market capitalization of $109.14 billion, McKesson is not just..

Labcorp Holdings Inc. (LH) Stock Analysis: Unveiling a 12.63% Potential Upside for Healthcare Investors

Labcorp Holdings Inc. (NYSE: LH) stands as a formidable player in the healthcare sector, specializing in diagnostics and research. With a market capitalization of $22.69 billion, Labcorp offers a comprehensive..

Thermo Fisher Scientific Inc (TMO): Investor Outlook with a 34.58% Potential Upside

Thermo Fisher Scientific Inc (NYSE: TMO), a prominent player in the healthcare sector, particularly in the diagnostics and research industry, presents a compelling opportunity for investors seeking growth within a..

Chemed Corp (CHE) Stock Analysis: Navigating a 16.4% Potential Upside in Healthcare

Chemed Corp (NYSE: CHE), a notable player in the healthcare sector, operates at the intersection of hospice care and essential plumbing services. With a market capitalization of $5.37 billion, Chemed’s..

Axsome Therapeutics, Inc. (AXSM): Investor Outlook on a Biotech Powerhouse with a 32.73% Potential Upside

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is rapidly emerging as a formidable player in the biotechnology sector, a magnet for investors seeking promising opportunities in the healthcare space. With a robust..

Quest Diagnostics (DGX) Stock Analysis: Exploring a 10.34% Potential Upside in Healthcare Diagnostics

Quest Diagnostics Incorporated (NYSE: DGX), a stalwart in the healthcare diagnostics sector, offers an intriguing opportunity for investors seeking exposure to the diagnostics and research industry. With a current market..

Abbott Laboratories (ABT) Stock Analysis: A Look at 28.59% Potential Upside for Healthcare Investors

Abbott Laboratories (NYSE: ABT), a leading player in the healthcare sector, continues to capture investor attention with its robust portfolio in the medical devices industry. With a market capitalization of..

Telix Pharmaceuticals Limited (TLX) Stock Analysis: 129.66% Potential Upside Beckons Investors

In the dynamic world of biotechnology, Telix Pharmaceuticals Limited (ASX: TLX) is making waves with its innovative approach to radiopharmaceuticals. With a market capitalization of $3.09 billion, the Australian-based company..

Inspire Medical Systems, Inc. (INSP) Stock Analysis: Unveiling a 44% Potential Upside in the Healthcare Sector

Inspire Medical Systems, Inc. (INSP), a prominent player in the healthcare sector specializing in medical devices, is drawing attention from investors with its innovative approach to treating obstructive sleep apnea..

ICON plc (ICLR) Stock Analysis: Evaluating Growth Potential with a 17.95% Upside

ICON plc (NASDAQ: ICLR), a prominent player in the healthcare sector, specifically within the Diagnostics & Research industry, is capturing attention with a potential upside of 17.95%. Headquartered in Dublin,..

TransMedics Group, Inc. (TMDX) Stock Report: Exploring a 60.19% Potential Upside in the Medical Devices Sector

TransMedics Group, Inc. (NASDAQ: TMDX), a pioneering player in the healthcare sector, stands at the forefront of advancing organ transplant therapy. With its innovative Organ Care System (OCS), the company..

RadNet, Inc. (RDNT) Stock Analysis: Exploring a 68.60% Potential Upside in the Diagnostics Sector

RadNet, Inc. (NASDAQ: RDNT), a prominent player in the healthcare sector, is making waves in the diagnostics and research industry. With a market capitalization of $4.25 billion, RadNet is carving..

Tempus AI, Inc. (TEM) Stock Analysis: Healthcare Innovator Poised for a 59% Upside

Tempus AI, Inc. (NASDAQ: TEM) is carving a niche in the healthcare sector through its advanced technology platform, strategically aligning itself with key industry players to revolutionize the healthcare landscape...

Bio-Techne Corp (TECH) Stock Analysis: Unlocking a 40.99% Potential Upside in the Biotechnology Sector

Bio-Techne Corp (NASDAQ: TECH), a pivotal player in the biotechnology industry, offers an intriguing opportunity for investors seeking exposure to the healthcare sector. Headquartered in Minneapolis, Minnesota, the company boasts..

Vaxcyte, Inc. (PCVX) Investor Outlook: An 86.71% Potential Upside Raises Eyebrows

Vaxcyte, Inc. (NASDAQ: PCVX), a clinical-stage vaccine innovation company, is making waves in the biotechnology sector. Known for its cutting-edge approach to developing vaccines aimed at preventing bacterial infectious diseases,..

AstraZeneca PLC (AZN) Stock Analysis: Navigating Growth with a $315 Billion Market Cap and Promising Analyst Ratings

AstraZeneca PLC (AZN), a key player in the global healthcare sector, continues to capture investor attention with its robust market presence and expansive pharmaceutical portfolio. With a market capitalization of..

Nuvalent, Inc. (NUVL) Stock Analysis: Biotechnology Innovator with a Potential 35% Upside

Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company with a focus on developing therapies for cancer patients, is making waves in the biotechnology sector. With a market capitalization of $8.29..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds